Beyondspring Inc. (BYSI) Stock Price & Analysis
Beyondspring Inc. (BYSI) rose 1.18% to USD 1.72 as of June 10, 2026 at 01:59 UTC, according to Nexqual real-time market data.
BYSI last closed at USD 1.7; the session ranged USD 1.66–1.75 on volume of 15,616 shares. Market capitalization is $70.73M, with a 52-week range of USD 1.18–3.44 (NCM). Source: Nexqual, June 10, 2026 at 01:59 UTC.
Key Statistics (as of June 10, 2026 at 01:59 UTC)
| Price | USD 1.72 |
|---|---|
| Change | ▲ 1.18% (up) |
| Previous Close | USD 1.7 |
| Open | USD 1.66 |
| Day Range | USD 1.66 – 1.75 |
| 52-Week Range | USD 1.18 – 3.44 |
| Volume | 15,616 shares |
| Market Cap | $70.73M |
| Exchange | NCM |
Technical Analysis (BYSI)
Nexqual's technical model rates BYSI "BUY" based on 5 bullish and 1 bearish signals across 124 daily candles, as of June 10, 2026 at 01:59 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 56.85 (neutral) |
| vs SMA50 | Above (USD 1.61) |
| MACD | 0.05 (positive) |
Analyst Ratings (BYSI)
Wall Street analysts rate BYSI "None", per Nexqual as of June 10, 2026 at 01:59 UTC.
| Consensus Rating | None |
|---|
Earnings (BYSI)
| Next Earnings Date | 2026-08-12 |
|---|
Source: Nexqual, June 10, 2026 at 01:59 UTC.
Financials & Fundamentals (BYSI)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| Current Ratio | 1.09 |
| Total Cash | $7.86M |
| Total Debt | $246,000 |
| Free Cash Flow | $12.51M |
Source: Nexqual, June 10, 2026 at 01:59 UTC.
Financial Health Score (BYSI)
Nexqual rates Beyondspring Inc.'s overall financial health "Mixed" across five dimensions, as of June 10, 2026 at 01:59 UTC.
| Growth | Mixed — Revenue +0.0% YoY (annual), slow |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Mixed — $8M cash, no debt |
| Cash Flow | Strong — FCF $13M, 926% margin |
| Efficiency | Mixed — No data |
Ownership (BYSI)
| Insider Ownership | +14.26% |
|---|---|
| Institutional Ownership | +14.55% |
| Shares Outstanding | 41.12M |
| Float | 31.69M |
| Short % of Float | +6.49% |
Source: Nexqual, June 10, 2026 at 01:59 UTC.
Leadership (BYSI)
Beyondspring Inc. is led by Lan Huang (age 54), Co-Founder, Chairman & CEO, per Nexqual as of June 10, 2026 at 01:59 UTC.
| Co-Founder, Chairman & CEO | Lan Huang (age 54) |
|---|---|
| Chief Scientific Officer | June Lu (age 59) |
| Senior Vice President of Development | John Mao |
Major Backers & Investors (BYSI)
Notable institutional backers of Beyondspring Inc. include Decheng Capital LLC, Fidelity, according to Nexqual as of June 10, 2026 at 01:59 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Decheng Capital LLC | 9.24% |
| Fidelity | 0.72% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 3.41% |
| BlackRock | 1.77% |
| Geode Capital | 0.91% |
| State Street | 0.56% |
| Northern Trust | 0.17% |
Source: Nexqual, June 10, 2026 at 01:59 UTC.
From Beyondspring Inc.'s Latest SEC 10-K Filing (filed 2026-03-25)
Key Strengths & Strategy (as disclosed to the SEC)
- BeyondSpring Inc., a clinical stage biopharmaceutical company, focuses on developing and selling clinical-stage biopharmaceutical therapies focused on oncology and immunology.
- The company operates through two segments: the Plinabulin pipeline and the TPD platform.
- The company's lead asset is Plinabulin, a selective immunomodulating microtubule-binding agent that has completed Phase III clinical trials for treatment of non-small cell lung cancer (NSCLC); and as an anti-cancer agent, as well as for the prevention of chemotherapy-induced neutropenia (CIN).
- It also develops Plinabulin in combination with Plinabulin+docetaxel vs. docetaxel alone for the treatment of NSCLC and epidermal growth factor receptor wild type.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| FULC | Fulcrum Therapeutics, Inc. | USD 3.52 | ▼ 4.61% |
| VRPX | Virpax Pharmaceuticals, Inc. | USD 0 | ▲ 0% |
| GRTX | Galera Therapeutics, Inc. | USD 0.09 | ▼ 2.11% |
| ATXI | Avenue Therapeutics, Inc. | USD 0.36 | ▲ 2.27% |
| ACIU | AC Immune SA | USD 2.26 | ▲ 0.44% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 01:59 UTC. This page is informational and not investment advice.